Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor
Chronic bone infection, as attends periodontitis, is often complicated by severe osteolysis. While LPS is believed to be central to the pathogenesis of the osteolytic lesion, the mechanisms by which this bacteria-derived molecule promotes bone resorption are unknown. We find that LPS induces bone ma...
Gespeichert in:
Veröffentlicht in: | The Journal of clinical investigation 1997-09, Vol.100 (6), p.1557-1565 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1565 |
---|---|
container_issue | 6 |
container_start_page | 1557 |
container_title | The Journal of clinical investigation |
container_volume | 100 |
creator | Abu-Amer, Y Ross, F P Edwards, J Teitelbaum, S L |
description | Chronic bone infection, as attends periodontitis, is often complicated by severe osteolysis. While LPS is believed to be central to the pathogenesis of the osteolytic lesion, the mechanisms by which this bacteria-derived molecule promotes bone resorption are unknown. We find that LPS induces bone marrow macrophages (BMMs) to express c-src, a protooncogene product that we demonstrate is a specific marker of commitment to the osteoclast phenotype. We next turned to possible soluble mediators of LPS-induced c-src. Of a number of osteoclastogenic cytokines tested, only TNF-alpha mirrors the c-src-enhancing effect of LPS. Suggesting that LPS augmentation of c-src is TNF-mediated, endotoxin sequentially induces BMM expression of TNF, followed by c-src. TNF and c-src expression, by cultured BMMs derived from LPS-injected mice, reflects duration of exposure to circulating endotoxin, intimating that endotoxin's effect in vivo is also mediated by TNF. Consistent with these findings, thalidomide (which antagonizes TNF action) attenuates c-src induction by LPS. An anti-TNF antibody blocks LPS enhancement of c-src mRNA, validating the cytokine's modulating role in vitro. Using BMMs of TNF receptor-deleted mice, we demonstrate that TNF induction of c-src is transmitted through the cytokine's p55, but not p75, receptor. Most importantly, LPS administered to wild-type mice prompts osteoclast precursor differentiation, manifest by profound osteoclastogenesis in marrow cultured ex vivo, and by a profusion of marrow-residing cells expressing the osteoclast marker tartrate resistant acid phosphatase, in vivo. In contrast, LPS does not substantially enhance osteoclast proliferation in mice lacking the p55TNF receptor, confirming that LPS-induced osteoclastogenesis is mediated by TNF in vivo via this receptor. Thus, therapy targeting TNF and/or its p55 receptor presents itself as a means of preventing the osteolysis of chronic bacterial infection. |
doi_str_mv | 10.1172/jci119679 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_508337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79283297</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-70aa9b57f68ade38c05c15bd65727592a17c04d31e5327d119063598cb71260a3</originalsourceid><addsrcrecordid>eNpVUctOwzAQ9AFUSuHAByDlhMQh4EccxwcOqOJRVAkOcLYcZ9u6SuJgO5X696S0qkBaabU7s4_RIHRF8B0hgt6vjSVE5kKeoDHGlKRSsOIMnYewxphkGc9GaCSpzAjNxmg9t53rXL0N2piV9raCNETb9LWOUCUuRHCm1iG6JbQQbEiGaKCyv3C5TWLfOJ-0YLzboQtt4lBvrE5sDMkH54kHA93QvECnC10HuDzkCfp6fvqcvqbz95fZ9HGemkzKmAqstSy5WOSFroAVBnNDeFnlXFDBJdVEGJxVjABnVFSDVpwzLgtTCkJzrNkEPez3dn05fGqgjV7XqvO20X6rnLbqP9LalVq6jeK4YEwM8zeHee--ewhRNTYYqGvdguuDEpIWjMod8XZP3GkPHhbHGwSrnRfqbTrbezFwr_8-dWQejGA_qyeJJQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79283297</pqid></control><display><type>article</type><title>Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Abu-Amer, Y ; Ross, F P ; Edwards, J ; Teitelbaum, S L</creator><creatorcontrib>Abu-Amer, Y ; Ross, F P ; Edwards, J ; Teitelbaum, S L</creatorcontrib><description>Chronic bone infection, as attends periodontitis, is often complicated by severe osteolysis. While LPS is believed to be central to the pathogenesis of the osteolytic lesion, the mechanisms by which this bacteria-derived molecule promotes bone resorption are unknown. We find that LPS induces bone marrow macrophages (BMMs) to express c-src, a protooncogene product that we demonstrate is a specific marker of commitment to the osteoclast phenotype. We next turned to possible soluble mediators of LPS-induced c-src. Of a number of osteoclastogenic cytokines tested, only TNF-alpha mirrors the c-src-enhancing effect of LPS. Suggesting that LPS augmentation of c-src is TNF-mediated, endotoxin sequentially induces BMM expression of TNF, followed by c-src. TNF and c-src expression, by cultured BMMs derived from LPS-injected mice, reflects duration of exposure to circulating endotoxin, intimating that endotoxin's effect in vivo is also mediated by TNF. Consistent with these findings, thalidomide (which antagonizes TNF action) attenuates c-src induction by LPS. An anti-TNF antibody blocks LPS enhancement of c-src mRNA, validating the cytokine's modulating role in vitro. Using BMMs of TNF receptor-deleted mice, we demonstrate that TNF induction of c-src is transmitted through the cytokine's p55, but not p75, receptor. Most importantly, LPS administered to wild-type mice prompts osteoclast precursor differentiation, manifest by profound osteoclastogenesis in marrow cultured ex vivo, and by a profusion of marrow-residing cells expressing the osteoclast marker tartrate resistant acid phosphatase, in vivo. In contrast, LPS does not substantially enhance osteoclast proliferation in mice lacking the p55TNF receptor, confirming that LPS-induced osteoclastogenesis is mediated by TNF in vivo via this receptor. Thus, therapy targeting TNF and/or its p55 receptor presents itself as a means of preventing the osteolysis of chronic bacterial infection.</description><identifier>ISSN: 0021-9738</identifier><identifier>DOI: 10.1172/jci119679</identifier><identifier>PMID: 9294124</identifier><language>eng</language><publisher>United States</publisher><subject>3T3 Cells ; Acid Phosphatase - metabolism ; AIDS/HIV ; Animals ; Antigens, CD - genetics ; Antigens, CD - physiology ; Biomarkers - analysis ; Bone Marrow Cells - drug effects ; Bone Marrow Cells - enzymology ; Bone Marrow Cells - metabolism ; Cell Differentiation - drug effects ; Cells, Cultured ; Coculture Techniques ; DNA, Complementary - analysis ; Dose-Response Relationship, Drug ; Genes, src - genetics ; Isoenzymes - metabolism ; Lipopolysaccharides - pharmacology ; Macrophages - drug effects ; Macrophages - metabolism ; Male ; Mice ; Mice, Inbred C3H ; Mice, Knockout ; Osteoclasts - enzymology ; Osteoclasts - metabolism ; Receptors, Tumor Necrosis Factor - genetics ; Receptors, Tumor Necrosis Factor - physiology ; Receptors, Tumor Necrosis Factor, Type I ; RNA, Messenger - analysis ; Tartrate-Resistant Acid Phosphatase ; Thalidomide - pharmacology ; Time Factors ; Tumor Necrosis Factor-alpha - pharmacology</subject><ispartof>The Journal of clinical investigation, 1997-09, Vol.100 (6), p.1557-1565</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-70aa9b57f68ade38c05c15bd65727592a17c04d31e5327d119063598cb71260a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC508337/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC508337/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9294124$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abu-Amer, Y</creatorcontrib><creatorcontrib>Ross, F P</creatorcontrib><creatorcontrib>Edwards, J</creatorcontrib><creatorcontrib>Teitelbaum, S L</creatorcontrib><title>Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>Chronic bone infection, as attends periodontitis, is often complicated by severe osteolysis. While LPS is believed to be central to the pathogenesis of the osteolytic lesion, the mechanisms by which this bacteria-derived molecule promotes bone resorption are unknown. We find that LPS induces bone marrow macrophages (BMMs) to express c-src, a protooncogene product that we demonstrate is a specific marker of commitment to the osteoclast phenotype. We next turned to possible soluble mediators of LPS-induced c-src. Of a number of osteoclastogenic cytokines tested, only TNF-alpha mirrors the c-src-enhancing effect of LPS. Suggesting that LPS augmentation of c-src is TNF-mediated, endotoxin sequentially induces BMM expression of TNF, followed by c-src. TNF and c-src expression, by cultured BMMs derived from LPS-injected mice, reflects duration of exposure to circulating endotoxin, intimating that endotoxin's effect in vivo is also mediated by TNF. Consistent with these findings, thalidomide (which antagonizes TNF action) attenuates c-src induction by LPS. An anti-TNF antibody blocks LPS enhancement of c-src mRNA, validating the cytokine's modulating role in vitro. Using BMMs of TNF receptor-deleted mice, we demonstrate that TNF induction of c-src is transmitted through the cytokine's p55, but not p75, receptor. Most importantly, LPS administered to wild-type mice prompts osteoclast precursor differentiation, manifest by profound osteoclastogenesis in marrow cultured ex vivo, and by a profusion of marrow-residing cells expressing the osteoclast marker tartrate resistant acid phosphatase, in vivo. In contrast, LPS does not substantially enhance osteoclast proliferation in mice lacking the p55TNF receptor, confirming that LPS-induced osteoclastogenesis is mediated by TNF in vivo via this receptor. Thus, therapy targeting TNF and/or its p55 receptor presents itself as a means of preventing the osteolysis of chronic bacterial infection.</description><subject>3T3 Cells</subject><subject>Acid Phosphatase - metabolism</subject><subject>AIDS/HIV</subject><subject>Animals</subject><subject>Antigens, CD - genetics</subject><subject>Antigens, CD - physiology</subject><subject>Biomarkers - analysis</subject><subject>Bone Marrow Cells - drug effects</subject><subject>Bone Marrow Cells - enzymology</subject><subject>Bone Marrow Cells - metabolism</subject><subject>Cell Differentiation - drug effects</subject><subject>Cells, Cultured</subject><subject>Coculture Techniques</subject><subject>DNA, Complementary - analysis</subject><subject>Dose-Response Relationship, Drug</subject><subject>Genes, src - genetics</subject><subject>Isoenzymes - metabolism</subject><subject>Lipopolysaccharides - pharmacology</subject><subject>Macrophages - drug effects</subject><subject>Macrophages - metabolism</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C3H</subject><subject>Mice, Knockout</subject><subject>Osteoclasts - enzymology</subject><subject>Osteoclasts - metabolism</subject><subject>Receptors, Tumor Necrosis Factor - genetics</subject><subject>Receptors, Tumor Necrosis Factor - physiology</subject><subject>Receptors, Tumor Necrosis Factor, Type I</subject><subject>RNA, Messenger - analysis</subject><subject>Tartrate-Resistant Acid Phosphatase</subject><subject>Thalidomide - pharmacology</subject><subject>Time Factors</subject><subject>Tumor Necrosis Factor-alpha - pharmacology</subject><issn>0021-9738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUctOwzAQ9AFUSuHAByDlhMQh4EccxwcOqOJRVAkOcLYcZ9u6SuJgO5X696S0qkBaabU7s4_RIHRF8B0hgt6vjSVE5kKeoDHGlKRSsOIMnYewxphkGc9GaCSpzAjNxmg9t53rXL0N2piV9raCNETb9LWOUCUuRHCm1iG6JbQQbEiGaKCyv3C5TWLfOJ-0YLzboQtt4lBvrE5sDMkH54kHA93QvECnC10HuDzkCfp6fvqcvqbz95fZ9HGemkzKmAqstSy5WOSFroAVBnNDeFnlXFDBJdVEGJxVjABnVFSDVpwzLgtTCkJzrNkEPez3dn05fGqgjV7XqvO20X6rnLbqP9LalVq6jeK4YEwM8zeHee--ewhRNTYYqGvdguuDEpIWjMod8XZP3GkPHhbHGwSrnRfqbTrbezFwr_8-dWQejGA_qyeJJQ</recordid><startdate>19970915</startdate><enddate>19970915</enddate><creator>Abu-Amer, Y</creator><creator>Ross, F P</creator><creator>Edwards, J</creator><creator>Teitelbaum, S L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19970915</creationdate><title>Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor</title><author>Abu-Amer, Y ; Ross, F P ; Edwards, J ; Teitelbaum, S L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-70aa9b57f68ade38c05c15bd65727592a17c04d31e5327d119063598cb71260a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>3T3 Cells</topic><topic>Acid Phosphatase - metabolism</topic><topic>AIDS/HIV</topic><topic>Animals</topic><topic>Antigens, CD - genetics</topic><topic>Antigens, CD - physiology</topic><topic>Biomarkers - analysis</topic><topic>Bone Marrow Cells - drug effects</topic><topic>Bone Marrow Cells - enzymology</topic><topic>Bone Marrow Cells - metabolism</topic><topic>Cell Differentiation - drug effects</topic><topic>Cells, Cultured</topic><topic>Coculture Techniques</topic><topic>DNA, Complementary - analysis</topic><topic>Dose-Response Relationship, Drug</topic><topic>Genes, src - genetics</topic><topic>Isoenzymes - metabolism</topic><topic>Lipopolysaccharides - pharmacology</topic><topic>Macrophages - drug effects</topic><topic>Macrophages - metabolism</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C3H</topic><topic>Mice, Knockout</topic><topic>Osteoclasts - enzymology</topic><topic>Osteoclasts - metabolism</topic><topic>Receptors, Tumor Necrosis Factor - genetics</topic><topic>Receptors, Tumor Necrosis Factor - physiology</topic><topic>Receptors, Tumor Necrosis Factor, Type I</topic><topic>RNA, Messenger - analysis</topic><topic>Tartrate-Resistant Acid Phosphatase</topic><topic>Thalidomide - pharmacology</topic><topic>Time Factors</topic><topic>Tumor Necrosis Factor-alpha - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abu-Amer, Y</creatorcontrib><creatorcontrib>Ross, F P</creatorcontrib><creatorcontrib>Edwards, J</creatorcontrib><creatorcontrib>Teitelbaum, S L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abu-Amer, Y</au><au>Ross, F P</au><au>Edwards, J</au><au>Teitelbaum, S L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>1997-09-15</date><risdate>1997</risdate><volume>100</volume><issue>6</issue><spage>1557</spage><epage>1565</epage><pages>1557-1565</pages><issn>0021-9738</issn><abstract>Chronic bone infection, as attends periodontitis, is often complicated by severe osteolysis. While LPS is believed to be central to the pathogenesis of the osteolytic lesion, the mechanisms by which this bacteria-derived molecule promotes bone resorption are unknown. We find that LPS induces bone marrow macrophages (BMMs) to express c-src, a protooncogene product that we demonstrate is a specific marker of commitment to the osteoclast phenotype. We next turned to possible soluble mediators of LPS-induced c-src. Of a number of osteoclastogenic cytokines tested, only TNF-alpha mirrors the c-src-enhancing effect of LPS. Suggesting that LPS augmentation of c-src is TNF-mediated, endotoxin sequentially induces BMM expression of TNF, followed by c-src. TNF and c-src expression, by cultured BMMs derived from LPS-injected mice, reflects duration of exposure to circulating endotoxin, intimating that endotoxin's effect in vivo is also mediated by TNF. Consistent with these findings, thalidomide (which antagonizes TNF action) attenuates c-src induction by LPS. An anti-TNF antibody blocks LPS enhancement of c-src mRNA, validating the cytokine's modulating role in vitro. Using BMMs of TNF receptor-deleted mice, we demonstrate that TNF induction of c-src is transmitted through the cytokine's p55, but not p75, receptor. Most importantly, LPS administered to wild-type mice prompts osteoclast precursor differentiation, manifest by profound osteoclastogenesis in marrow cultured ex vivo, and by a profusion of marrow-residing cells expressing the osteoclast marker tartrate resistant acid phosphatase, in vivo. In contrast, LPS does not substantially enhance osteoclast proliferation in mice lacking the p55TNF receptor, confirming that LPS-induced osteoclastogenesis is mediated by TNF in vivo via this receptor. Thus, therapy targeting TNF and/or its p55 receptor presents itself as a means of preventing the osteolysis of chronic bacterial infection.</abstract><cop>United States</cop><pmid>9294124</pmid><doi>10.1172/jci119679</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9738 |
ispartof | The Journal of clinical investigation, 1997-09, Vol.100 (6), p.1557-1565 |
issn | 0021-9738 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_508337 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
subjects | 3T3 Cells Acid Phosphatase - metabolism AIDS/HIV Animals Antigens, CD - genetics Antigens, CD - physiology Biomarkers - analysis Bone Marrow Cells - drug effects Bone Marrow Cells - enzymology Bone Marrow Cells - metabolism Cell Differentiation - drug effects Cells, Cultured Coculture Techniques DNA, Complementary - analysis Dose-Response Relationship, Drug Genes, src - genetics Isoenzymes - metabolism Lipopolysaccharides - pharmacology Macrophages - drug effects Macrophages - metabolism Male Mice Mice, Inbred C3H Mice, Knockout Osteoclasts - enzymology Osteoclasts - metabolism Receptors, Tumor Necrosis Factor - genetics Receptors, Tumor Necrosis Factor - physiology Receptors, Tumor Necrosis Factor, Type I RNA, Messenger - analysis Tartrate-Resistant Acid Phosphatase Thalidomide - pharmacology Time Factors Tumor Necrosis Factor-alpha - pharmacology |
title | Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T22%3A00%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipopolysaccharide-stimulated%20osteoclastogenesis%20is%20mediated%20by%20tumor%20necrosis%20factor%20via%20its%20P55%20receptor&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Abu-Amer,%20Y&rft.date=1997-09-15&rft.volume=100&rft.issue=6&rft.spage=1557&rft.epage=1565&rft.pages=1557-1565&rft.issn=0021-9738&rft_id=info:doi/10.1172/jci119679&rft_dat=%3Cproquest_pubme%3E79283297%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79283297&rft_id=info:pmid/9294124&rfr_iscdi=true |